Announcement on Subsidiary HB0025 Injection Initiating Phase III Clinical Trial
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference:
Announcement on Subsidiary HB0025 Injection Initiating Phase III Clinical Trial
Filed with SSE · · 2 pages · Chinese
On 6ix: 6ix.com/news/announcement-on-subsidiary-hb0025-injection-initiating-phase-iii-clinical-trial
Release
Zhejiang Huahai Pharmaceutical Co., Ltd. on 6ix
Earlier from Zhejiang Huahai Pharmaceutical
- Announcement on Progress in Drug Clinical Trials by Subsidiary
- Announcement on Convening the Q3 2025 Performance Briefing
- Announcement on the Subsidiary Passing On-site Inspection by FDA
- Announcement on Not Revising Downward the Conversion Price of ""HUAHAI Convertible Bonds"
- Report for Q3 2025
Later from Zhejiang Huahai Pharmaceutical
- Announcement on Optional Repurchase Results of "Huahai Convertible Bonds"
- Announcement on Release of Pledge of Partial Equity of Shareholder
- On-Site Inspection Report of Zheshang Securities Co., Ltd. on Continuous Supervision over ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD. in 2025
- Announcement on Expected Decrease in Performance for 2025
- Announcement on Obtaining the Notice on Approval of Drug Supplement Application
Follow Zhejiang Huahai Pharmaceutical into a list and get an email when it puts out news.
Follow Zhejiang Huahai Pharmaceutical